Carvedilol Articles
Boeh Mannheim's Carvedilol Approved In Germany
26 March 1997
Carvedilol Backed For Heart Failure In USA
10 March 1997
New Products Drive Strong Growth At SB
24 February 1997
Analysts Cast Doubt On Kredex' Potential In USA
17 February 1997
Boeh Mannnheim's Carvedilol Approved In Austria
10 February 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
SmithKline Beecham 3rd Qtr Earnings Leap 20%
28 October 1996
Canada Clears SB And BMT's Coreg
14 October 1996
Second Heart Failure Launch For Carvedilol
16 September 1996
First Launch Of Carvedilol For CHF; Approval In Spain
2 September 1996
SmithKline Beecham: A Leader In Spanish Market
19 August 1996
European and London Stock Market
17 June 1996
Europe Stock Comment
13 May 1996
SB Fails To Get CHF Backing For Carvedilol
13 May 1996
New Cardiovascular Drugs Reviewed
6 May 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
First Launch Of SB's Carvedilol For Heart Failure
29 January 1996
Astra Merck Gets Bucindolol Rights
18 December 1995
UK Prescription Medicine Code Of Practice Review
4 December 1995
EUROPE STOCK COMMENT
20 November 1995
SB's Carvedilol Cuts CHF Deaths By 67%, AHA Told
20 November 1995
SmithKline Beecham/ Boeh Mannheim: carvedilol
16 October 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
SmithKline Beecham's Coreg Approved For Hypertension In The USA
25 September 1995
SB's Carvedilol Effective In Congestive Heart Failure
13 February 1995
Highlights Of SmithKline's R&D Portfolio
2 January 1995
CORANGE 2000: A REVIEW AND FUTURE STRATEGY
11 July 1994
DAIICHI ENTERING NEW PRODUCT PHASE
26 July 1993
DAIICHI LAUNCHES ONCE-DAILY ARTIST
7 June 1993
NEW PRODUCTS ON JAPAN TARIFF LIST
12 April 1993
US CARVEDILOL NDA "IMMINENT," SAYS SB
15 February 1993
Daiichi expects improvement in 92
22 June 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
